Orbimed Advisors Llc - Aug 4, 2023 Form 4/A - Amendment Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Director
Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Stock symbol
IKNA
Transactions as of
Aug 4, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/21/2023, 05:02 PM
Date Of Original Report
Sep 14, 2023
Previous filing
Aug 2, 2023
Next filing
Aug 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IKNA Non-Voting Common Stock Award +153K +2.82% 5.58M Aug 4, 2023 See Footnote F1, F2, F3, F4, F6
holding IKNA Common Stock 2.1M Aug 4, 2023 See Footnote F1, F4, F6
holding IKNA Common Stock 91K Aug 4, 2023 See Footnote F5, F6
holding IKNA Non-Voting Common Stock 157K Aug 4, 2023 See Footnote F2, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Series A Preferred Stock Award +353K 353K Aug 4, 2023 Non-Voting Common Stock 353K See Footnote F3, F4, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 14, 2023, the Reporting Persons filed a Form 4 that inadvertently reported the acquisition of shares of the Issuer's common stock rather than shares of Non-Voting Common Stock. This amendment corrects the type of shares of Issuer common stock acquired by the Reporting Persons and the amount of securities beneficially owned by the Reporting Persons.
F2 Each share of Non-Voting Common Stock is convertible into one share of the Issuer's common stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation that may be increased or decreased by the holder upon 61 days' notice to the Issuer.
F3 Received in exchange for shares of Class A common stock of Pionyr Immunotherapeutics, Inc. ("Pionyr") in accordance with the terms of the Agreement and Plan of Merger, dated August 4, 2023, by and among the Issuer, Portsmouth Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Portsmouth Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Pionyr, and Fortis Advisors LLC, as securityholder agent.
F4 These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
F5 These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
F6 This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Bonita is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
F7 Following approval by the Issuer's stockholders of the conversion of the Issuer's Series A Preferred Stock into shares of the Issuer's common stock, each share of Series A Preferred Stock is automatically convertible into one share of the Issuer's voting common stock; provided that if a holder of the Issuer's Series A Preferred Stock was a holder of the Issuer's Non-Voting Common Stock prior to such conversion, such holder will receive shares of the Issuer's Non-Voting Common Stock to the extent such conversion would result in such holder beneficially owning more than 9.99% of the Issuer's voting common stock.